Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

Exclusion Criteria

• •1. Patients on invasive mechanical ventilation (e.g., endotracheal intubation)
• •2. Chronic home oxygen utilization
• •3. Home or current use of immunosuppressive medications (including steroids)
• •4. Women who are pregnant, breastfeeding, or become pregnant during the study
• •5. Patients on non-invasive positive pressure ventilation
• •6. Patients on \>12 liters per minute via non-rebreather (NRB) or \>80% oxygen via high flow nasal cannula
• •7. Patients who, in the opinion of the PI, have impending respiratory failure, defined as requiring rapidly escalating oxygen supplementation
• •8. Patients with a hemoglobin \<9 mg/dL
• •9. Patients diagnosed with Stage 4 or 5 chronic kidney disease (CKD)
• •10. Patients with diagnosed New York Heart Association (NYHA) class 4 or 5 congestive heart failure
• •11. Patients with a left ventricular assist device (LVAD)
• •12. Patients with thromboembolic phenomena
• •13. Patients with Type 2 and above heart block
• •14. Patients with established positive bacterial blood cultures prior to enrollment
• •15. Patients with ongoing pericardial effusion or ascites
• •16. Patients with clinically significant arrhythmia
• •17. Patients with liver function tests (ALT or AST) \>3x normal
• •18. Patients with untreated HIV infection
• •19. Patients diagnosed with end-stage organ disease